Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CytoDyn Inc.CYDY · Entity 5856 | Director | October 18, 2021 | October 20, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CytoDyn Inc.
Report date October 18, 2021 · Filed October 20, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.39 · Expires 2031-10-18 | Direct | 225,000 |
Reported balance
After 2021-10-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-10-18 · Grant · Acquired 225,000 · Balance 225,000 F1: The options will vest in 12 equal monthly installments beginning on July 1, 2021, subject to Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended) through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options will vest in 12 equal monthly installments beginning on July 1, 2021, subject to Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended) through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 18, 2021 Filed Oct 20, 2021 20:09 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantNon-qualified Stock Option · Derivative | 225,000 | $0.00 Strike: $1.39 | $0.00 |
DisclosureSEC source: 0000899243-21-040746 · doc4.xml · derivative · entry 1 Naydenov Jordan G · CIK 0001469618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2031-10-18 F1 · derivative.exercise_date: The options will vest in 12 equal monthly installments beginning on July 1, 2021, subject to Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended) through the applicable vesting date. Read SEC document |
| September 23, 2021 Filed Sep 28, 2021 01:26 UTC | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionWarrant (Right to Buy) · Derivative | 266,668 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0000899243-21-037904 · doc4.xml · derivative · entry 12 Naydenov Jordan G · CIK 0001469618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 266,668 shares Expires 2023-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On September 23, 2021, as an inducement to exercise, the Issuer and the Reporting Person agreed to amend three warrants held by the Reporting Person (the "Warrants") to purchase a total of 644,444 shares of the Issuer's common stock, par value $0.001 per share (the "Common Stock"), pursuant to which twice as many shares could be purchased for double the total original exercise price. Read SEC document |
| September 23, 2021 Filed Sep 28, 2021 01:26 UTC | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionWarrant (Right to Buy) · Derivative | 133,332 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0000899243-21-037904 · doc4.xml · derivative · entry 11 Naydenov Jordan G · CIK 0001469618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 133,332 shares Expires 2022-07-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On September 23, 2021, as an inducement to exercise, the Issuer and the Reporting Person agreed to amend three warrants held by the Reporting Person (the "Warrants") to purchase a total of 644,444 shares of the Issuer's common stock, par value $0.001 per share (the "Common Stock"), pursuant to which twice as many shares could be purchased for double the total original exercise price. Read SEC document |
| September 23, 2021 Filed Sep 28, 2021 01:26 UTC | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionWarrant (Right to Buy) · Derivative | 888,888 | Not disclosed Strike: $0.45 | Not disclosed |
DisclosureSEC source: 0000899243-21-037904 · doc4.xml · derivative · entry 10 Naydenov Jordan G · CIK 0001469618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 888,888 shares Expires 2024-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On September 23, 2021, as an inducement to exercise, the Issuer and the Reporting Person agreed to amend three warrants held by the Reporting Person (the "Warrants") to purchase a total of 644,444 shares of the Issuer's common stock, par value $0.001 per share (the "Common Stock"), pursuant to which twice as many shares could be purchased for double the total original exercise price. Read SEC document |
| September 23, 2021 Filed Sep 28, 2021 01:26 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantWarrant (Right to Buy) · Derivative | 266,668 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0000899243-21-037904 · doc4.xml · derivative · entry 9 Naydenov Jordan G · CIK 0001469618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,668 Underlying: Common Stock · 266,668 shares Expires 2023-01-31 F1 · price: On September 23, 2021, as an inducement to exercise, the Issuer and the Reporting Person agreed to amend three warrants held by the Reporting Person (the "Warrants") to purchase a total of 644,444 shares of the Issuer's common stock, par value $0.001 per share (the "Common Stock"), pursuant to which twice as many shares could be purchased for double the total original exercise price. Read SEC document |
| September 23, 2021 Filed Sep 28, 2021 01:26 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantWarrant (Right to Buy) · Derivative | 133,332 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0000899243-21-037904 · doc4.xml · derivative · entry 8 Naydenov Jordan G · CIK 0001469618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,332 Underlying: Common Stock · 133,332 shares Expires 2022-07-26 F1 · price: On September 23, 2021, as an inducement to exercise, the Issuer and the Reporting Person agreed to amend three warrants held by the Reporting Person (the "Warrants") to purchase a total of 644,444 shares of the Issuer's common stock, par value $0.001 per share (the "Common Stock"), pursuant to which twice as many shares could be purchased for double the total original exercise price. Read SEC document |
| September 23, 2021 Filed Sep 28, 2021 01:26 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantWarrant (Right to Buy) · Derivative | 888,888 | Not disclosed Strike: $0.45 | Not disclosed |
DisclosureSEC source: 0000899243-21-037904 · doc4.xml · derivative · entry 7 Naydenov Jordan G · CIK 0001469618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 888,888 Underlying: Common Stock · 888,888 shares Expires 2024-12-13 F1 · price: On September 23, 2021, as an inducement to exercise, the Issuer and the Reporting Person agreed to amend three warrants held by the Reporting Person (the "Warrants") to purchase a total of 644,444 shares of the Issuer's common stock, par value $0.001 per share (the "Common Stock"), pursuant to which twice as many shares could be purchased for double the total original exercise price. Read SEC document |
| September 23, 2021 Filed Sep 28, 2021 01:26 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerWarrant (Right to Buy) · Derivative | 133,334 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0000899243-21-037904 · doc4.xml · derivative · entry 6 Naydenov Jordan G · CIK 0001469618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 133,334 shares Expires 2023-01-31 F1 · price: On September 23, 2021, as an inducement to exercise, the Issuer and the Reporting Person agreed to amend three warrants held by the Reporting Person (the "Warrants") to purchase a total of 644,444 shares of the Issuer's common stock, par value $0.001 per share (the "Common Stock"), pursuant to which twice as many shares could be purchased for double the total original exercise price. Read SEC document |
| September 23, 2021 Filed Sep 28, 2021 01:26 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerWarrant (Right to Buy) · Derivative | 66,666 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0000899243-21-037904 · doc4.xml · derivative · entry 5 Naydenov Jordan G · CIK 0001469618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 66,666 shares Expires 2022-07-26 F1 · price: On September 23, 2021, as an inducement to exercise, the Issuer and the Reporting Person agreed to amend three warrants held by the Reporting Person (the "Warrants") to purchase a total of 644,444 shares of the Issuer's common stock, par value $0.001 per share (the "Common Stock"), pursuant to which twice as many shares could be purchased for double the total original exercise price. Read SEC document |
| September 23, 2021 Filed Sep 28, 2021 01:26 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerWarrant (Right to Buy) · Derivative | 444,444 | Not disclosed Strike: $0.45 | Not disclosed |
DisclosureSEC source: 0000899243-21-037904 · doc4.xml · derivative · entry 4 Naydenov Jordan G · CIK 0001469618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 444,444 shares Expires 2024-12-13 F1 · price: On September 23, 2021, as an inducement to exercise, the Issuer and the Reporting Person agreed to amend three warrants held by the Reporting Person (the "Warrants") to purchase a total of 644,444 shares of the Issuer's common stock, par value $0.001 per share (the "Common Stock"), pursuant to which twice as many shares could be purchased for double the total original exercise price. Read SEC document |
| September 23, 2021 Filed Sep 28, 2021 01:26 UTC | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionCommon Stock | 266,668 | $0.75 | $200,001.00 |
DisclosureSEC source: 0000899243-21-037904 · doc4.xml · nonDerivative · entry 3 Naydenov Jordan G · CIK 0001469618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,990,211 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 23, 2021 Filed Sep 28, 2021 01:26 UTC | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionCommon Stock | 133,332 | $0.75 | $99,999.00 |
DisclosureSEC source: 0000899243-21-037904 · doc4.xml · nonDerivative · entry 2 Naydenov Jordan G · CIK 0001469618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,723,543 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 23, 2021 Filed Sep 28, 2021 01:26 UTC | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionCommon Stock | 888,888 | $0.45 | $399,999.60 |
DisclosureSEC source: 0000899243-21-037904 · doc4.xml · nonDerivative · entry 1 Naydenov Jordan G · CIK 0001469618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,590,211 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 19, 2021 Filed Apr 21, 2021 22:27 UTC | CytoDyn Inc. CYDY · Entity 5856 | OtherWarrant (right to buy) · Derivative | 250,000 | $0.00 Strike: $1.35 | $0.00 |
DisclosureSEC source: 0001807094-21-000003 · primary_doc.xml · derivative · entry 2 Naydenov Jordan G · CIK 0001469618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 250,000 shares Expires 2021-05-10 Read SEC document |
| April 19, 2021 Filed Apr 21, 2021 22:27 UTC | CytoDyn Inc. CYDY · Entity 5856 | OtherCommon Stock | 250,000 | $1.35 | $337,500.00 |
DisclosureSEC source: 0001807094-21-000003 · primary_doc.xml · nonDerivative · entry 1 Naydenov Jordan G · CIK 0001469618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,701,323 Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 02:09 UTC | CytoDyn Inc. CYDY · Entity 5856 | PurchaseCommon Stock | 193,500 | $2.57 | $497,295.00 |
DisclosureSEC source: 0001807094-20-000026 · primary_doc.xml · nonDerivative · entry 1 Naydenov Jordan G · CIK 0001469618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,451,323 F1 · price: This transaction was executed in multiple trades at prices ranging from $2.50 to $2.61. The price above reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected Read SEC document |
| October 23, 2020 Filed Oct 26, 2020 23:45 UTC | CytoDyn Inc. CYDY · Entity 5856 | PurchaseCommon Stock | 120,000 | $2.49 | $298,308.00 |
DisclosureSEC source: 0001807094-20-000024 · primary_doc.xml · nonDerivative · entry 1 Naydenov Jordan G · CIK 0001469618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,257,823 F1 · price: This transaction was executed in multiple trades at prices ranging from $2.4701 to $2.49. The price reported reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 25, 2020 Filed Jun 27, 2020 01:39 UTC Amendment | CytoDyn Inc. CYDY · Entity 5856 | GrantNon-qualified Stock Option · Derivative | 225,000 | $0.00 Strike: $6.15 | $0.00 |
DisclosureSEC source: 0001807094-20-000011 · primary_doc.xml · derivative · entry 1 Naydenov Jordan G · CIK 0001469618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2030-06-25 F1 · derivative.exercise_date: 56,250 shares vest on August 31, 2020; the balance vests in equal amounts on November 30, 2020, February 28, 2021 and May 31, 2021, subject to amendment to the equity incentive plan. F2 · derivative.expiration_date: This Form 4 amends the expiration date of the option incorrectly reported on the original Form 4 filed with the SEC on June 26, 2020. Read SEC document |
| June 25, 2020 Filed Jun 27, 2020 01:19 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantNon-qualified Stock · Derivative | 225,000 | $0.00 Strike: $6.15 | $0.00 |
DisclosureSEC source: 0001807094-20-000009 · primary_doc.xml · derivative · entry 1 Naydenov Jordan G · CIK 0001469618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2020-06-25 F1 · derivative.exercise_date: 56,250 shares vest on August 31, 2020. The balance vests in equal amounts on November 30, 2020, February 28, 2021 and May 31, 2021, subject to amendment to the equity incentive plan. Read SEC document |
| December 19, 2019 Filed Dec 24, 2019 00:06 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Option (right to buy) · Derivative | 750,000 | $0.00 Strike: $0.63 | $0.00 |
DisclosureSEC source: 0000899243-19-030000 · doc4.xml · derivative · entry 1 Naydenov Jordan G · CIK 0001469618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750,000 Underlying: Common Stock · 750,000 shares Expires 2029-12-19 Read SEC document |
| December 13, 2019 Filed Dec 17, 2019 21:32 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantWarrants (right to buy) · Derivative | 625,000 | Not disclosed Strike: $0.45 | Not disclosed |
DisclosureSEC source: 0000899243-19-029421 · doc4.xml · derivative · entry 2 Naydenov Jordan G · CIK 0001469618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 625,000 Underlying: Common Stock · 625,000 shares Expires 2024-12-13 F1 · price: The reported securities were purchased together, as part of a registered direct offering, at a combined price of $0.30 per share of common stock and related warrants. Read SEC document |
| December 13, 2019 Filed Dec 17, 2019 21:32 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 833,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-029421 · doc4.xml · nonDerivative · entry 1 Naydenov Jordan G · CIK 0001469618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,137,823 F1 · price: The reported securities were purchased together, as part of a registered direct offering, at a combined price of $0.30 per share of common stock and related warrants. Read SEC document |
| June 18, 2019 Filed Jun 20, 2019 01:05 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 100,000 | $0.00 Strike: $0.52 | $0.00 |
DisclosureSEC source: 0000899243-19-017516 · doc4.xml · derivative · entry 1 Naydenov Jordan G · CIK 0001469618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2029-06-18 F1 · derivative.exercise_date: The options will vest in four equal quarterly installments, commencing on September 1, 2019. Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:25 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerWarrants (right to buy) · Derivative | 250,000 | Not disclosed Strike: $1.35 | Not disclosed |
DisclosureSEC source: 0000899243-18-029183 · doc4.xml · derivative · entry 13 Naydenov Jordan G · CIK 0001469618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 250,000 shares Expires 2021-05-10 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:25 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerWarrants (right to buy) · Derivative | 66,666 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0000899243-18-029183 · doc4.xml · derivative · entry 12 Naydenov Jordan G · CIK 0001469618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 66,666 shares Expires 2022-07-26 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:25 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerWarrants (right to buy) · Derivative | 133,334 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0000899243-18-029183 · doc4.xml · derivative · entry 11 Naydenov Jordan G · CIK 0001469618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 133,334 shares Expires 2023-01-31 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:25 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerStock Options (right to buy) · Derivative | 100,000 | Not disclosed Strike: $0.49 | Not disclosed |
DisclosureSEC source: 0000899243-18-029183 · doc4.xml · derivative · entry 10 Naydenov Jordan G · CIK 0001469618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2028-06-08 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). F3 · derivative.exercise_date: The options vest in four equal quarterly installments commencing on September 1, 2018. Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:25 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerStock Options (right to buy) · Derivative | 50,000 | Not disclosed Strike: $0.80 | Not disclosed |
DisclosureSEC source: 0000899243-18-029183 · doc4.xml · derivative · entry 9 Naydenov Jordan G · CIK 0001469618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2023-02-15 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:25 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerStock Options (right to buy) · Derivative | 96,397 | Not disclosed Strike: $0.56 | Not disclosed |
DisclosureSEC source: 0000899243-18-029183 · doc4.xml · derivative · entry 8 Naydenov Jordan G · CIK 0001469618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 96,397 shares Expires 2028-02-07 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:25 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerStock Options (right to buy) · Derivative | 75,000 | Not disclosed Strike: $0.57 | Not disclosed |
DisclosureSEC source: 0000899243-18-029183 · doc4.xml · derivative · entry 7 Naydenov Jordan G · CIK 0001469618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,000 shares Expires 2027-06-01 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:25 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerStock Options (right to buy) · Derivative | 50,000 | Not disclosed Strike: $1.09 | Not disclosed |
DisclosureSEC source: 0000899243-18-029183 · doc4.xml · derivative · entry 6 Naydenov Jordan G · CIK 0001469618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2026-06-01 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:25 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerStock Options (right to buy) · Derivative | 50,000 | Not disclosed Strike: $0.98 | Not disclosed |
DisclosureSEC source: 0000899243-18-029183 · doc4.xml · derivative · entry 5 Naydenov Jordan G · CIK 0001469618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2025-06-01 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:25 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerStock Options (right to buy) · Derivative | 25,000 | Not disclosed Strike: $1.55 | Not disclosed |
DisclosureSEC source: 0000899243-18-029183 · doc4.xml · derivative · entry 4 Naydenov Jordan G · CIK 0001469618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2022-06-01 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:25 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerStock Options (right to buy) · Derivative | 50,000 | Not disclosed Strike: $2.00 | Not disclosed |
DisclosureSEC source: 0000899243-18-029183 · doc4.xml · derivative · entry 3 Naydenov Jordan G · CIK 0001469618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2021-08-08 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:25 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerStock Options (right to buy) · Derivative | 50,000 | Not disclosed Strike: $0.66 | Not disclosed |
DisclosureSEC source: 0000899243-18-029183 · doc4.xml · derivative · entry 2 Naydenov Jordan G · CIK 0001469618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2019-06-01 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:25 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerCommon Stock | 5,304,490 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-029183 · doc4.xml · nonDerivative · entry 1 Naydenov Jordan G · CIK 0001469618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 13:03 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantWarrants (right to buy) · Derivative | 250,000 | Not disclosed Strike: $1.35 | Not disclosed |
DisclosureSEC source: 0000899243-18-029260 · doc4.xml · derivative · entry 13 Naydenov Jordan G · CIK 0001469618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2021-05-10 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 13:03 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantWarrants (right to buy) · Derivative | 66,666 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0000899243-18-029260 · doc4.xml · derivative · entry 12 Naydenov Jordan G · CIK 0001469618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,666 Underlying: Common Stock · 66,666 shares Expires 2022-07-26 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 13:03 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantWarrants (right to buy) · Derivative | 133,334 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0000899243-18-029260 · doc4.xml · derivative · entry 11 Naydenov Jordan G · CIK 0001469618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,334 Underlying: Common Stock · 133,334 shares Expires 2023-01-31 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 13:03 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 100,000 | Not disclosed Strike: $0.49 | Not disclosed |
DisclosureSEC source: 0000899243-18-029260 · doc4.xml · derivative · entry 10 Naydenov Jordan G · CIK 0001469618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2028-06-08 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). F3 · derivative.exercise_date: The options (including predecessor options) vest in four equal quarterly installments commencing on September 1, 2018. Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 13:03 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 50,000 | Not disclosed Strike: $0.80 | Not disclosed |
DisclosureSEC source: 0000899243-18-029260 · doc4.xml · derivative · entry 9 Naydenov Jordan G · CIK 0001469618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2023-02-15 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 13:03 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 96,397 | Not disclosed Strike: $0.56 | Not disclosed |
DisclosureSEC source: 0000899243-18-029260 · doc4.xml · derivative · entry 8 Naydenov Jordan G · CIK 0001469618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,397 Underlying: Common Stock · 96,397 shares Expires 2028-02-07 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 13:03 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 75,000 | Not disclosed Strike: $0.57 | Not disclosed |
DisclosureSEC source: 0000899243-18-029260 · doc4.xml · derivative · entry 7 Naydenov Jordan G · CIK 0001469618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2027-06-01 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 13:03 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 50,000 | Not disclosed Strike: $1.09 | Not disclosed |
DisclosureSEC source: 0000899243-18-029260 · doc4.xml · derivative · entry 6 Naydenov Jordan G · CIK 0001469618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2026-06-01 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 13:03 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 50,000 | Not disclosed Strike: $0.98 | Not disclosed |
DisclosureSEC source: 0000899243-18-029260 · doc4.xml · derivative · entry 5 Naydenov Jordan G · CIK 0001469618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2025-06-01 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 13:03 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 25,000 | Not disclosed Strike: $1.55 | Not disclosed |
DisclosureSEC source: 0000899243-18-029260 · doc4.xml · derivative · entry 4 Naydenov Jordan G · CIK 0001469618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2022-06-01 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 13:03 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 50,000 | Not disclosed Strike: $2.00 | Not disclosed |
DisclosureSEC source: 0000899243-18-029260 · doc4.xml · derivative · entry 3 Naydenov Jordan G · CIK 0001469618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2021-08-08 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 13:03 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 50,000 | Not disclosed Strike: $0.66 | Not disclosed |
DisclosureSEC source: 0000899243-18-029260 · doc4.xml · derivative · entry 2 Naydenov Jordan G · CIK 0001469618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2019-06-01 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 13:03 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 5,304,490 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-029260 · doc4.xml · nonDerivative · entry 1 Naydenov Jordan G · CIK 0001469618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,304,490 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| June 08, 2018 Filed Jun 12, 2018 21:53 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 100,000 | $0.00 Strike: $0.49 | $0.00 |
DisclosureSEC source: 0000899243-18-016225 · doc4.xml · derivative · entry 1 Naydenov Jordan G · CIK 0001469618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2028-06-08 F1 · derivative.exercise_date: The options will vest in four equal quarterly installments commencing on September 1, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.